VolitionRx initiates pilot study to assess effectiveness of NuQ assays for ovarian cancer

Jan 21 2015

The pilot study is designed to assess whether VolitionRx’s NuQ^® assays could be used as an initial screening tool for ovarian cancer

VolitionRx Limited (OTCQB: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced it has signed an agreement to commence a pilot ovarian cancer study in collaboration with Singapore General Hospital (SGH). Blood and tissue samples collected from 40 patients will be assessed to establish the feasibility of VolitionRx’s proprietary NuQ^® assays in detecting ovarian cancer. If this test proves to be accurate, it could offer hope as an early-stage screening tool.

The collaboration with SGH will be VolitionRx’s first to focus solely on patients from an Asian ethnic background. The Hospital will provide 20 matched blood and tissue samples from patients with ovarian cancer as well as blood samples from 20 healthy donors. The anonymised and blinded samples will be analysed by VolitionRx’s team and will be the first matched tissue and blood samples to be assessed using its NuQ^® assays. On completion of the analyses, the data will be unblinded and together the parties will evaluate the performance of the test.

Dr. Jake Micallef, Chief Scientific Officer of VolitionRx, added:

This pilot study is incredibly important for us. By working with a small patient population, we are hopeful that we can collect initial data to demonstrate the performance of our Nucleosomics^® technology through a simple blood test to detect ovarian cancer in a non-invasive way. If the pilot results are favourable and we successfully commercialize the test, we intend to set up a center of excellence in Singapore to service the whole Asian region with regard to screening for ovarian cancer, a cancer for which early detection is crucial.

VolitionRx will retain the intellectual property from the study.

Other clinical trials assessing the effectiveness of Volition’s assays include:

• A 4,800 patient retrospective symptomatic population study in colorectal cancer at Hvidovre Hospital, University of Copenhagen, Denmark
• A 14,000 patient prospective screening study in colorectal cancer at Hvidovre Hospital, University of Copenhagen, Denmark
• A 4,000 patient prospective study that involves patients with the 20 most prevalent cancers at University Hospital in Bonn, Germany
• A 600 patient prospective confirmatory study in lung cancer at University Hospital in Bonn, Germany
• A 250 patient prospective study in colorectal cancer at CHU-UCL Mont Godinne Hospital, Belgium
• A retrospective study with MD Anderson, Texas, to establish the efficacy of VolitionRx’s NuQ^® tests to distinguish anaplastic prostate cancer, a particularly aggressive form of the disease, from typical castration resistant prostate cancer (CRPC), the less aggressive form.
• A prospective study with the University of Oxford, United Kingdom, to assess VolitionRx’s NuQ^® tests for the diagnosis of endometriosis.

Source: http://www.volitionrx.com/